Modulight Spotlights: LASER-SHARP RESEARCH – February 2022
Tag Archives: ML6500
Light delivery optimization for H&N cancer treatment
Results
Illumination with one fiber
Some level of tissue heating was observed at all used light intensities. At lower intensities (60-100 mW/cm), less than 5% of the tumor was subjected to >60 ⁰C temperature, a point where irreversible thermal damage will immediately occur (photothermal ablation). At intensities of 150-200 mW/cm, 15-20% of the tumor was at >60 ⁰C temperature. At 400 mW/cm, which is FDA-recommended light irradiance for iPDT, a… READ MORE
Protected: New approach for targeted PDT of glioblastoma
There is no excerpt because this is a protected post.
Vision-sparing targeted phototherapy for uveal melanoma
Preliminary investigation of AU-011
Related Modulight products and Services
Related Publications
Virus-Like Particle-Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens
Rhonda C. Kines, Cynthia D. Thompson, Sean Spring, Zhenyu Li, Elisabet de los Pinos, Stephen Monks and John T. Schiller
Cancer Immunology Research, 2021, 9 (6)
A Phase 1b/2 Open-label Clinical Trial to Evaluate the Safety and Efficacy… READ MORE
Protected: Light-induced drug delivery with indocyanine green liposomes
There is no excerpt because this is a protected post.
Novel antimicrobial phototherapy against emerging infectious diseases
Results
PIAS-treated pathogens were effectively eradicated upon NIR illumination. The efficacy of PIAS was dependent on the NIR light dose, 50 J/cm2 eradicating all MRSA from the rat nasal tract (Figure 1). PIAS also saved all mice from fatal MRSA infections, similar to VCM+RFP antibiotics and even more effectively than VCM antibiotics alone (Figure 2). Unlike the antibiotics, PIAS acted selectively on the target pathogen and did… READ MORE
Modulight Spotlights: LASER-SHARP RESEARCH – April 2021
